Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA83781
Max Phase: Preclinical
Molecular Formula: C22H25NO
Molecular Weight: 319.45
Molecule Type: Small molecule
Associated Items:
ID: ALA83781
Max Phase: Preclinical
Molecular Formula: C22H25NO
Molecular Weight: 319.45
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Oc1ccc(C#CCCN2CCC(Cc3ccccc3)CC2)cc1
Standard InChI: InChI=1S/C22H25NO/c24-22-11-9-19(10-12-22)6-4-5-15-23-16-13-21(14-17-23)18-20-7-2-1-3-8-20/h1-3,7-12,21,24H,5,13-18H2
Standard InChI Key: DQZBYMUDSJTGLY-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 319.45 | Molecular Weight (Monoisotopic): 319.1936 | AlogP: 4.09 | #Rotatable Bonds: 4 |
Polar Surface Area: 23.47 | Molecular Species: BASE | HBA: 2 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.74 | CX Basic pKa: 8.94 | CX LogP: 4.68 | CX LogD: 3.44 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.86 | Np Likeness Score: -0.34 |
1. Wright JL, Gregory TF, Bigge CF, Boxer PA, Serpa K, Meltzer LT, Wise LD, Cai SX, Hawkinson JE, Konkoy CS, Whittemore ER, Woodward RM, Zhou ZL.. (1999) Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines., 42 (13): [PMID:10395488] [10.1021/jm990148x] |
2. Wright JL, Gregory TF, Boxer PA, Meltzer LT, Serpa KA, Wise LD.. (1999) Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists., 9 (19): [PMID:10522697] [10.1016/s0960-894x(99)00482-5] |
3. Wright JL, Gregory TF, Kesten SR, Boxer PA, Serpa KA, Meltzer LT, Wise LD, Espitia SA, Konkoy CS, Whittemore ER, Woodward RM.. (2000) Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines., 43 (18): [PMID:10978188] [10.1021/jm000023o] |
4. Gregory TF, Wright JL, Wise LD, Meltzer LT, Serpa KA, Konkoy CS, Whittemore ER, Woodward RM.. (2000) Parallel synthesis of a series of subtype-selective NMDA receptor antagonists., 10 (6): [PMID:10741546] [10.1016/s0960-894x(00)00035-4] |
Source(1):